IPCA Laboratories Ltd 26 th August, 2013 BUY
|
|
- Janel Ferguson
- 5 years ago
- Views:
Transcription
1 Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY IPCA Laboratories Ltd 26 th August, 2013 BUY CMP(As on 24/8/13) Rs Target Price Rs BSE Code NSE Code IPCALAB Market Cap (Rs Cr.) Week High/Low / Industry Pharmaceuticals Face Value Rs.2.00 Shares O/S Cr. EPS Book Value P/E P/B 5.06 Shareholding Pattern Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients. Exports to over 120 countries, now account for nearly 61% of its income. The company has posted highest strong quarterly performance for the quarter ending June The Revenues from operations on consolidated basis increased by around 26% at Rs crores vs Rs crores y-o-y. Operating profit jumped about 21% at about Rs crores as against Rs crores in the previous quarter. Overall R&D cost in this quarter was around Rs crores which includes about Rs.3.14 crores of capital expenditure and Rs.32 crores of revenue expenditure. As a result of it operating profit margins declined about 101bps at 21.23%. The net profit skyrocketed by 67% at Rs crore for the quarter as compared to Rs crore. EPS for the quarter stood at Rs The company incurred a capital expenditure of around Rs.47 crores in the quarter. Total revenue from formulations business grew by 29% at Rs crores as against Rs crores in Q1FY13. Revenue from domestic branded formulations grew by 12% at Rs crores from Rs crores y-o-y and export formulations revenues surged sharply by 47% at Rs crores vis-à-vis Rs crores. Revenues from API moved up by 17% at Rs cr. as compared to Rs cr. in Q1FY13. Domestic API revenues grew 16% at Rs cr vs Rs cr. y-o-y. Export API revenues jumped by 17% at Rs cr. from Rs cr. in Q1FY13. Valuation Research Analyst: Vineeta Mahnot research@hemonline.com With robust product pipeline, increasing market share in key products; revival of ani-malaria segment revenues; Ipca Labs Ltd. revenue stream looks visible. Approval of Indore SEZ would be a growth driver in near term. We believe the company is trading at an attractive valuation at 17.21x and 13.95x of FY14EPS of Rs and FY15EPS of Rs We initiate a BUY on the stock with a target price of Rs.780 (appreciation of about 25%) with the medium to long term investment horizon. For Private Circulation Only 1 Hem Research
2 Business Details Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US. It is one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM- Europe, WHO-Geneva and many more. Ipca is a therapy leader in India for anti-malarials with a market-share of over 34% with a fast expanding presence in the international market as well. It also lead in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. APIs Ipca has emerged as one of India's top exporters of APIs with nearly 25% of the turnover coming from APIs. Regulated markets like the USA, Canada, Europe and Australia account for 75% of its API exports. It is one of the world's largest manufacturers of APIs - Atenolol (anti-hypertensive), Chloroquine Phosphate (antimalarial), Furosemide (diuretic), Hydroxychloroquine Sulphate (NSAID), Metoprolol Succinate (anti-hypertensive), Metoprolol Tartrate (anti-hypertensive) and Pyrantel Salts (anthelmintic) - besides being one of the largest suppliers of these APIs worldwide. For over 20 years, Ipca has been playing a lead role in the Indian APIs market, both in the anti-malarial and anti-hypertensive therapeutic segments. Formulations - Branded-India Ipca manufactures over 350 formulations in virtually every dosage form: oral solids and liquids, dry powders for suspension, and injectables (liquid and dry). Its finished formulations are available in over 500,000 retail shops that are catered to by a network of over 1500 wholesalers sales and marketing personnel service over 200,000 doctors across the country. It has leading brands in 5 therapeutic areas, with 4 of branded formulations being ranked among the Top-300 Indian brands by ORG-IMS. Its top 10 brands are Zerodol (Aceclofenac+combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm(Metoclopramide), Rapither (Artemotil), Tenoric (Atenolol + Chlorthalidone), Lumerax (Artemether + Lumefantrine), Etova(Etodolac), Malirid (Primaquine) and Folitrax (Methotrexate). International Ipca's formulations basket includes generics for the developed markets and branded formulations for emerging markets. Formulations account for 67% of export turnover, making Ipca one of India's largest formulation exporters. Ipca has over 1500 products registered in 70 countries, and another 600 are in the process of registration in 50 countries. More than half of its formulations business is backed by our own APIs. Ipca promote more than 60 brands of formulations in over 36 countries of Asia, Africa, CIS and South America. For Private Circulation Only 2 Hem Research
3 Upward Guidance Ipca s management has given strong guidance for financial year ending March Revenue growth for FY14 is expected to be in the range of 18-20% with more emphasis on the upper end. Looking at the first quarter performance, they expect to revise revenue guidance upwards post Q2 or so. Promotional business is expected to grow by around 25% to 30% and institutional business is estimated to achieve business of around Rs.460 crores. The company is market leader in the anti-malaria segment with about 50% market share in FY13. Anti-malarial segment after witnessing a subdued first half performance is expected to perform well in later half and can become around Rs.800 crores kind of business in about 2-3 years time with very good pipeline. The company has leadership in rheumatoid arthiritis with substantial market share. R&D expenditure for the whole year would be around 4%. EBITDA margin is expected to be around 22 percent. Tax rate would be staying in the range of 25% to 27% during the quarters but would not exceed 26% for the year. So, overall growth for the current year should be good with very good profitability. Strong capex ahead Capex for the current year is expected to be around Rs.300 crore plus. The company is putting up a Greenfield project at Baroda as API Facility; Rs.100 crores are expected to be spend on this facility. Around Rs.80 crores are to be utilized for purchase of new machines like high-speed blister machines, high-speed tabulating machine and some like high-speed card retainer [ph] machines. And remaining Rs.120 crores will be spend on maintenance and lot of other things. The company has current field force strength at 3,800 and expects to focus more on increasing productivity rather than increasing field force. For Private Circulation Only 3 Hem Research
4 Commissioning of Indore SEZ plant Ipca exports its generic formulations to US, Europe, South Africa and few more countries. US formulations business was limited due to capacity constraint. The USFDA has inspected the Indore facility of the company in April. The approval is on the cards and the management expects it to be either in end of August or September. Upon approval the company would start commercial production of formulations for the US market through marketing and distribution partners probably in Q3 or Q4 of the current year. With the commencement of production at this facility and with launch of new products; US market will grow and gain significant market share. The company has cumulative filings of 35 ANDAs out of which 15 have been approved and 8 products are already commericalised. The company has about 50 products at various stages of development including 505(b)2 projects/ sustained release formulations and also plans to file 8 to 10 ANDAs every year going ahead. For Private Circulation Only 4 Hem Research
5 Consolidated Profit & Loss Account Rs. Crore Particulars FY11 FY12 FY13 FY14E FY15E Net sales Growth 24.19% 19.23% 19.30% 19.80% Expenditure EBITDA Growth 37.28% 21.36% 18.48% 21.98% EBITDA margin 19.69% 21.76% 22.15% 22.00% 22.40% Other income Depreciation & Amortisation EBIT EBIT margin 17.19% 19.43% 19.58% 19.35% 19.85% Interest Gain/Loss on foreign ex. Translation (52.73) PBT Tax PAT Minority interest (0.08) Share of profits in Associates (0.43) (0.86) Adjusted PAT Growth Net Profit margins Exceptional item Reported PAT Equity Shares Adjusted EPS Ratios Particulars FY11 FY12 FY13 FY14E FY15E Return on Equity Return on Capital employed Debt/Equity Asset turnover Current Ratio Book value per share For Private Circulation Only 5 Hem Research
6 Balance Sheet Rs. Crore Particulars FY11 FY12 FY13 FY14E FY15E Share Capital Reserves & Surplus , , , Shareholders funds Pref. Sh. Issues by subsidiaries Borrowings Deferred tax liability Minority Interest Sources of funds Gross block , Accumulated Depreciation Net block Capital work in progress Investments Deffered tax assets Goodwill on consolidation Inventories , Sundry debtors Cash and bank balance Other current assets Loans and advances Total current assets 1, , , , , Current liabilities and provisions Net current assets , , , Misc exp Uses of funds 1, , , , , For Private Circulation Only 6 Hem Research
7 Quarterly Financial Highlights Rs. Crore Particulars Q1FY14 Q1FY13 Q4FY13 YoY% QoQ% Revenues Expenditures Operating Profit Adjusted Net Profit (4.85) OPM% (101bps) 4bps NPM % bps (232bps) Adjusted EPS (4.85) Past Price movement of the stock For Private Circulation Only 7 Hem Research
8 HEM SECURITIES LIMITED MEMBER-BSE,CDSL, SEBI REGISTERED CATEGORY I MERCHANT BANKER MUMBAI OFFICE: 14/15, KHATAU BLDG., IST FLOOR, 40, BANK STREET, FORT, MUMBAI PHONE FAX JAIPUR OFFICE: , JAIPUR TOWERS, M I ROAD, JAIPUR PHONE FAX GROUP COMPANIES HEM FINLEASE PRIVATE LIMITED MEMBER-NSE HEM MULTI COMMODITIES PRIVATE LIMITED MEMBER-NCDEX, MCX HEM FINANCIAL SERVICES LIMITED NBFC REGISTERED WITH RBI For Private Circulation Only 8 Hem Research
9 Disclaimer & Disclosure: This document is prepared for our clients only, on the basis of publicly available information and other sources believed to be reliable. Whilst we are not soliciting any action based on this information, all care has been taken to ensure that the facts are accurate, fair and reasonable. This information is not intended as an offer or solicitation for the purchase or sell of any financial instrument and at any point should not be considered as an investment advise. Reader is requested to rely on his own decision and may take independent professional advise before investing. Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited, Directors and any of its employees shall not be responsible for the content. The person accessing this information specifically agrees to exempt Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and further agrees to hold Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The companies and its affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material may from time to time, have long or short positions in, and buy or sell the securities there of, company (ies) mentioned here in and the same have acted upon or used the information prior to, or immediately following the publication. Disclosure of Interest Statement Company Name 1. Analyst Ownership of the Stock No 2. Hem & its Group Company Ownership of the Stock Yes 3. Hem & its Group Companies Director Ownership of the Stock Yes 4. Broking relationship with company covered No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. For Private Circulation Only 9 Hem Research
Va Tech Wabag Ltd. 11 th March, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Va Tech Wabag Ltd. 11 th March, 2014 BUY CMP Target Price Rs.691.30 Rs.870.00 VA Tech Wabag is Indian multinational player technology focused
More informationR.S. Software (India) Ltd. 11 th August, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY R.S. Software (India) Ltd. 11 th August, 2014 BUY CMP Rs.430.00 Target Price Rs.600.00 BSE Code 517447 NSE Code RSSOFTWARE Market Cap (Rs
More informationNIIT Technologies Ltd. 15 th February, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY NIIT Technologies Ltd. 15 th February, 2016 BUY CMP Target Price Rs.500.95 Rs.645.00 BSE Code 532541 Market Cap (Rs Cr.) 3065.81 52 Week
More informationTech Mahindra Ltd 21 st September, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Tech Mahindra Ltd 21 st September, 2013 BUY CMP Target Price Rs.1298.60 Rs.1650.00 Tech Mahindra is a global systems integrator and business
More informationIdea Cellular Ltd. 19 th January, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Idea Cellular Ltd. 19 th January, 2015 BUY CMP Target Price Rs.155.20 Rs.210.00 BSE Code 532822 Market Cap (Rs Cr.) 55,832.96 52 Week High/Low
More informationCeat Ltd 1 st June, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Ceat Ltd 1 st June, 2013 BUY CMP Target Price Rs.107.75 Rs.140.00 Ceat is India s leading tyre company with over 50 years of presence.
More informationGabriel India Ltd. 4 th November, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Gabriel India Ltd. 4 th November, 2014 BUY CMP(As on 3/11/2014) Rs.83.40 Target Price Rs.115.00 BSE Code 505714 NSE Code GABRIEL Market
More informationCamlin Fine Sciences Ltd. 27 th June, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Camlin Fine Sciences Ltd. 27 th June, 2015 BUY CMP Target Price Rs.111.85 Rs.145.00 Camlin Fine Sciences is one of the India's leading
More informationMunjal Showa Ltd 30 th May, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Munjal Showa Ltd 30 th May, 2012 CMP Target Price Rs.79.00 Rs.100.00 Munjal Showa Limited in Hero Group's joint venture with Showa Corporation,
More informationV-Guard Industries Ltd 9 th June, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY V-Guard Industries Ltd 9 th June, 2012 CMP Rs.215.00 The V-Guard Group has emerged as one of the most trusted brand in India. VGIL plans
More informationGranules India Ltd. 21 st July, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Granules India Ltd. 21 st July, 2012 CMP Target Price Rs.149.30 Rs.200.00 Granules India is among the leading global manufacturer of highvolume
More informationAlembic Pharmaceuticals Ltd 25 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Alembic Pharmaceuticals Ltd 25 th September, 2012 CMP Target Price Rs.70.85 Rs.90.00 Alembic Pharma continues to maintain its market share
More informationPidilite Industries Ltd 10 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Pidilite Industries Ltd 10 th September, 2012 CMP(as on 8/9/2012) Target Price Rs.200.50 Rs.260.00 Pidilite Industries Ltd. has been a
More informationDCB Bank Ltd. 18 th August, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY DCB Bank Ltd. 18 th August, 2014 BUY CMP Rs.81.40 Target Price Rs.120.00 BSE Code 532772 NSE Code DCBBANK Market Cap (Rs Cr.) 2040.24 52
More informationMadras Cements Ltd 9 th October, 2012 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Madras Cements Ltd 9 th October, 2012 BUY CMP Target Price Rs.186.35 Rs.240.00 Madras Cements Ltd is the flagship company of the Ramco
More informationMinda Corporation Ltd. 29 th December, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Minda Corporation Ltd. 29 th December, 2015 BUY CMP Rs.89.40 Target Price Rs.120.00 BSE Code 538962 Market Cap (Rs Cr.) 1871.14 52 Week
More informationGateway Distriparks Ltd 1 st July, 2011 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Gateway Distriparks Ltd 1 st July, 2011 BUY CMP Rs 126.75 Target Price Rs 170.00 BSE Code 532622 NSE Code GDL Market Cap (Rs Mn) 13699.51
More informationSteel Strips Wheels Ltd. 6 th August, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Steel Strips Wheels Ltd. 6 th August, 2016 BUY CMP Rs.511.80 Target Price Rs.640.00 BSE Code 513262 Market Cap (Rs Cr.) 794.42 52 Week
More informationCarborundum Universal Ltd 18 th July, 2011 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Carborundum Universal Ltd 18 th July, 2011 BUY CMP Rs 302.00 Target Price Rs 360.00 Large capacity expansions and major business acquisitions,
More informationGlenmark Pharmaceuticals Ltd 23 rd May, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Glenmark Pharmaceuticals Ltd 23 rd May, 2012 CMP(As on 22/5/2012) Rs.357.00 Target Price Rs 450.00 As per ORG IMS MAT March 2012 data,
More informationBalaji Amines Ltd 22/11/2017 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING Balaji Amines Ltd 22/11/2017 BUY CMP Rs. 600.75 Target Price Rs 780.00 BSE Code 530999 NSE Code BALAMINES Market Cap (Rs crore) Rs.1946.43
More informationIPO Report ICICI SECURITIES LTD SUBSCRIBE. Valuation. IPO Details. Research Analyst : Astha Jain
IPO Report ICICI SECURITIES LTD SUBSCRIBE IPO Details Issue Date 22 nd Mar-26 th Mar 2018 Price Band 519-520/Share Bid Lot 28 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE Offer For Sale
More informationSUBSCRIBE. IPO Report HDFC ASSET MANAGEMENT COMPANY LTD. IPO Details. Research Analyst : Astha Jain
IPO Report HDFC ASSET MANAGEMENT COMPANY LTD SUBSCRIBE IPO Details Issue Date 25 th July-27 th July 2018 Price Band 1095-1100/Share Bid Lot 13 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE
More informationGHCL Ltd. 19 th September, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY GHCL Ltd. 19 th September, 2016 BUY CMP (BSE) Rs.253.00 Target Price Rs.310.00 BSE Code 500171 Market Cap (Rs Cr.) 2530.49 52 Week High/Low
More informationMeghmani Organics Ltd 24th Aug 2017 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING Meghmani Organics Ltd 24th Aug 2017 BUY CMP Rs. 72.65 Target Price Rs 95.00 BSE Code 532865 NSE Code MEGH Market Cap (Rs crore) Rs. 1847.49
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationAVOID. IPO Report GARDEN REACH SHIPBUILDERS & ENGINEERS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report AVOID IPO Details Issue Date 24 th Sept-26 th Sept 2018 Price Band 115-118/Share * Bid Lot 120 & in multiplethereof Face Value Rs 10/Share Listing BSE, NSE Offer For Sale 29,210,760 Eq Shares
More informationLONG TERM SUBSCRIBE. IPO Report HINDUSTAN AERONAUTICS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report HINDUSTAN AERONAUTICS LTD LONG TERM SUBSCRIBE IPO Details Issue Date 16 th Mar-20 th Mar 2018 Price Band Bid Lot Face Value Listing Offer For Sale Fresh Issue ---- Pre Issue Eq Shares Post Issue
More informationSUBSCRIBE. IPO Report BHARAT DYNAMICS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report BHARAT DYNAMICS LTD SUBSCRIBE IPO Details Issue Date 13 th Mar-15 th Mar 2018 Price Band 413-428/Share* Bid Lot 35 & in multiplethereof Face Value Rs 10/Share Listing BSE, NSE Offer For Sale
More informationParag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months
2QFY2019 Result Update Dairy Products November 6, 2018 Parag Milk Foods Performance Update Y/E March (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 573 505 13.7% 549 4.4% EBITDA 58 50 16.3% 60-2.7%
More information3QFY09 revenues in line but adjusted margins beat KIE. No changes in estimates for FY E
India Daily Summary - January 29, 2009 LUPIN January 29, 2009 Pharmaceuticals LUPN.BO, Rs562 Rating Sector coverage view Target Price (Rs) BUY Attractive 950 52W High -Low (Rs) 782-438 Market Cap (Rs bn)
More informationIpca Laboratories Ltd.
Ipca Laboratories Ltd. Corporate Presentation Dec 2017 Company Overview Incorporation : 1949 Present Management : Since 1975 Total income F. Y. 2016-17 : ` 3178.87 Crs / US$ 474 Mn Exports F. Y. 2016-17
More informationJ.B. Chemicals & Pharmaceuticals Ltd.
Oct-16 Nov-16 Nov-16 Dec-16 Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 Apr-17 May-17 Jun-17 Jun-17 Jul-17 Aug-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 146 J.B. Chemicals & Pharmaceuticals Ltd. October
More informationAlembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months
1QFY2011 Result Update Pharmaceutical August 2, 2010 Alembic Performance Highlights Y/E March (Rs cr) 1QFY2011 4QFY2010 % chg (qoq) 1QFY2010 % chg (yoy) Net Sales 279 267 4.6 291 (4.0) Other Income 1 1
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationMarket Snap 12 th May 2018
Weekly ary Market Snap 12 th May 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34915.38 34983.59 35596.15 34977.74
More informationSpiceJet ACCUMULATE. Performance Highlights. 4QFY2010 Result Update I Aviation
4QFY2010 Result Update I Aviation June 3, 2010 SpiceJet Performance Highlights For 4QFY2010, SpiceJet s Top-line grew 34.3% yoy but fell 12.8% qoq to Rs560cr, slightly lower than our estimate of Rs590cr.
More informationParag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months
1QFY2019 Result Update Dairy Products August 8, 2018 Parag Milk Foods Performance Update Y/E March (` cr) Q1FY19 Q1FY18 % yoy Q4FY18 % qoq Net sales 549 413 32.9 518 5.9 EBITDA 60 29 103% 55 8.4% EBITDA
More informationJK Paper Ltd 16/02/2018 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING JK Paper Ltd 16/02/2018 BUY CMP Rs 137.55 Target Price Rs 180.00 BSE Code 532162 NSE Code JKPAPER Market Cap (Rs crore) Rs.2414.00 52
More informationBulls maintain their grip for the third week in a row
Weekly Commentary Market Snap 17 th November 2018 www.hemsecurities.com www.hemsecurities.com BROKING INVESTMENT BANKING RESEARCH DISTRIBUTION DEPOSITORY Index Previous Close Open High Low Close Change
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationMargin (%) PAT (Rs cr)
4 Recommendation HOLD Reiterating positive outlook CMP (27/7/2015) Rs. 115 Target Price Rs. 125 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN IN Market Cap
More informationSHRIRAM TRANSPORT FINANCE COMPANY LTD
27 June 2017 SHRIRAM TRANSPORT FINANCE COMPANY LTD CMP INR 975 Initiating Coverage (BUY) Target Price INR 1225 Stock Details Industry Finance (including NBFCs) Bloomberg Code SHTF:IN BSE Code 511218 Face
More informationIpca Laboratories ACCUMULATE. Performance Highlights. `533 Target Price CMP. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 Months
May-12 Nov-12 May-13 Nov-13 May-14 Nov-14 May-15 Nov-15 May-16 Nov-16 May-17 2QFY2018 Result Update Pharmaceutical November 28, 2017 Ipca Laboratories Performance Highlights % chg % chg Y/E March (` cr)
More informationULTRAMARINE & PIGMENTS LTD
02 December 2016 ULTRAMARINE & PIGMENTS LTD CMP INR 170 Initiating Coverage (BUY) Target Price INR 226 Stock Details Industry SPECIALTY CHEMICALS Bloomberg Code UMP:IN BSE Code 506685 Face Value (Rs.)
More informationPhillips Carbon Black Ltd
4 Recommendation BOOK PROFITS Pain not yet over CMP (09/02/2015)* Rs. 131 Phillips Carbon Black (PCB) reported results in line with expectations; with EBITDA margins at 10.0% vs 9.3% in Q2FY15. The company
More informationFY2017 FY2018E FY2019E
Jul-12 Dec-12 May-13 Oct-13 Mar-14 Aug-14 Jan-15 Jun-15 Nov-15 Apr-16 Sep-16 Feb-17 Jul-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Lupin Performance Highlights Y/E March (`cr) 2QFY2018
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationIPCA Laboratories Ltd
STOCK POINTER IPCA Laboratories Ltd BUY Target Price Rs. 870 CMP Rs. 735 4QFY20E PE 20X Index Details Sensex 35,219 Nifty 10,740 Industry Pharma Scrip Details Mkt Cap (Rs cr) 9,261 BVPS (Rs) 196.1 O/s
More informationCapacity expansion to drive growth and profitability
STOCK POINTER Swaraj Engines Ltd. BUY Target Price `656 CMP `41 FY14 PE 6.9x Index Details Sensex 17,853 Nifty 5,39 BSE 1 5,367 Industry Auto parts Scrip Details Mkt Cap (` cr) 59 BVPS (`) 161 O/s Shares
More informationKey estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,
: price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn
More informationAmara Raja Batteries Ltd.
Amara Raja Batteries Ltd. CMP : ` 219.70 Target Price ` 260 BSE Code : 500008 AMARAJABAT Market Cap (` Cr) 3836 Equity Cap (` Cr) 17.08 Face Value 1 Book Value 52.67 EPS (`) 14.76 Dividend Yield (%) 1
More informationColgate-Palmolive ACCUMULATE. Performance Highlights. 4QFY2010 Result Update I FMCG
4QFY2010 Result Update I FMCG May 27, 2010 Colgate-Palmolive Performance Highlights ACCUMULATE CMP Target Price Rs715 Rs752 We highlight the fact that the current quarter results are not comparable yoy/qoq,
More informationMarket Snap 26 th May 2018
Weekly ary Market Snap 26 th May 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34848.30 34873.16 35017.93 34302.89
More informationDr Reddy s Laboratories
: price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia
More informationKey Highlights. YoY (% change) Q1FY10. QoQ % Particulars 2Q FY10 2Q FY09 Realizations per tone 31,899 53,436-40% 30,462 5% Source: Company
29th October, 2009 Key Data INR CMP 743 Target Price 646 Earlier target price 481 Bloomberg Code JSTL IN Reuters Code JSTL.BO BSE Code 500228 NSE Code JSWSTEEL Face Value (INR) 10 Market Cap (INR bn) 142
More informationCMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452
2QFY18 Result Update October 31, 2017 Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452 US Biz to Remain Weak; Maintain Led by weak performance in the US markets, (LPC) has delivered a weak
More informationCanara Bank Securities Ltd
A WHOLLY OWNED SUBSIDIARY OF CANARA BANK Ajanta Pharma (IC) LTP : 1481 Date :26 th Dec 2017 Stock Info Sector Market Target 1728 Holding Period Pharmaceuticals & Drugs Domestic & International 9-11 months
More informationCarborundum Universal Ltd 14/11/2017 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING Carborundum Universal Ltd 14/11/2017 BUY CMP Rs. 370.00 Target Price Rs 480.00 BSE Code 513375 NSE Code CARBORUNIV Market Cap (Rs crore)
More informationAurobindo Pharma Ltd.
. Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More informationGMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months
2QFY2019 Result Update Industrial Machinery October 26, 2018 GMM Pfaudler Limited Performance Update Standalone (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 99.2 93.2 29.8% 76.4 6.4% EBITDA 16.0 15.3
More informationLupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart
2QFY2017 Result Update Pharmaceutical November 11, 2016 Lupin Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg qoq 2QFY2016 % chg yoy Net sales 4,212 4,316 (2.4) 3,193 31.9 Other income
More informationKey estimate revision. Year FY14 23,28,609 3,48,027 1,40, FY15E 25,74,029 3,94,133 1,69,
: price: EPS: How does our one year outlook change? We retain our positive stance on TTMT driven by continued strong performance at JLR on both revenues & margins and expected reduction in losses at standalone
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationStandalone Quarterly results (YE Mar) 1QFY14 1QFY15 % yoy FY13 FY14 % yoy
India I Equities Healthcare Result Update 15 July 2014 Unichem Laboratories Recovery in sight; Buy Key takeaways Results slightly above our estimates. Unichem Laboratories (Unichem) revenue grew 9.6% yoy,
More informationReligare Investment Call
v-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 v-18 Q2FY19 Result Update Q2FY19 Result Update BUY CMP (Rs) 5,813 Target Price (Rs) 6,519 Potential Upside 12.1% Sensex
More informationMarket Snap 02 nd June 2018
Weekly ary Market Snap 02 nd June 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34924.87 35074.32 35438.22 34735.11
More informationCipla BUY. Performance Highlights CMP. `310 Target Price `369. 2QFY2012 Result Update Pharmaceutical. Investment Period 12 months
2QFY2012 Result Update Pharmaceutical November 16, 2011 Cipla Performance Highlights Y/E March (` cr) 2QFY2012 1QFY2012 % chg qoq 2QFY2011 % chg yoy Net sales 1,731 1,550 11.7 1,580 9.6 Other income 71
More informationCMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7
2QFY18 Result Update November 23, 2017 Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7 High Order Book Provides Revenue Visibility (PMPL) has delivered a healthy performance in 2QFY18.
More informationDr. Reddy s Laboratories
2QFY2017 Result Update Pharmaceutical November 7, 2016 Dr. Reddy s Laboratories Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 3,586 3,235 10.9 3,989
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationCipla REDUCE. Performance Highlights. CMP Target Price `564 `490. 2QFY2017 Result Update Pharmaceutical. Investment Period - 3-Year Daily Price Chart
2QFY2017 Result Update Pharmaceutical November 11, 2016 Cipla Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg qoq 2QFY2016 % chg yoy Net sales 3,672 3,500 4.9 3,379 8.7 Other income 106
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationBloomberg Code: ATA IN
Auto OEM: 3-Wheelers Atul Feb Auto 03, 2015 Ltd India Research Stock Broking Bloomberg Code: ATA IN Stable quarter led by surge in exports volumes (TP revised ) : Operating revenue, EBITDA and PAT grew
More informationInvestor Presentation 2 nd Qtr. - FY 2018
Investor Presentation 2 nd Qtr. - FY 2018 31 st October, 2017 1 of 33 India Disclosure Index 2017 Ajanta s Ranking in Next 100 Listed Companies (Based on Market Cap) 1 st 2 nd 3 rd Voluntary Disclosure
More informationITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs.
: price: EPS: Relative better visibility despite the smoke, Maintain BUY ITC reported revenues of Rs.~87.2bn (+13% y-o-y), operating profits of Rs.32.8bn (+15% y-o-y) and PAT of Rs.~23.8bn (+16% y-o-y).
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationDr Reddy s Laboratories
1QFY2017 Result Update Pharmaceutical July 29, 2016 Dr Reddy s Laboratories Performance Highlights Y/E March (` cr) 1QFY2017 4QFY2016 % chg (qoq) 1QFY2016 % chg (yoy) Net sales 3,235 3,756 (13.9) 3,758
More informationNRB BEARINGS LTD CMP. 16 July 2018 INR 164. Target Price. Initiating Coverage (BUY) INR 200
16 July 2018 NRB BEARINGS LTD CMP INR 164 Initiating Coverage (BUY) Target Price INR 200 Stock Details Industry Industrial Machinery Bloomberg Code NRBBR:IN BSE Code 530367 Face Value (Rs.) 2.00 Market
More informationLupin NEUTRAL. Performance Highlights. CMP `1,838 Target Price - 2QFY2016 Result Update Pharmaceutical. Investment Period -
2QFY2016 Result Update Pharmaceutical November 10, 2015 Lupin Performance Highlights Y/E March (` cr) 1QFY2016 4QFY2015 % chg qoq 1QFY2015 % chg yoy Net sales 3,178 3,074 3.4 3,117 2.0 Other income 184
More informationCadila Healthcare NEUTRAL. Performance Highlights CMP. `390 Target Price - 2QFY2017 Result Update Pharmaceutical. Investment Period -
2QFY2017 Result Update Pharmaceutical November 7, 2016 Cadila Healthcare Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 2,336 2,216 5.4 2,267 3.1 Other
More informationCMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630
4QFY17 Result Update June 02,2017 Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630 Decent Performance to Continue; Maintain Crompton Greaves Consumer Electricals (CGCEL) has delivered a
More informationCadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514
3QFY15 Result Update Institutional Equities Cadila Healthcare 11 February 2015 Reuters: CADI.BO; Bloomberg: CDH IN Stable Performance Cadila Healthcare s (CHL) 3QFY15 earnings were in line with our expectations
More informationCMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630
1QFY18 Result Update July 28,2017 CMP* (Rs) 208 Bloomberg Ticker CROMPTON IN Market Cap. (Rs bn) 130.6 Free Float (%) 65.6 Shares O/S (mn) 630 Channel De-stocking Impairs Top-line; Recovery Ahead Crompton
More informationAurobindo Pharma BUY. Performance Highlights CMP. `109 Target Price `156. 1QFY2013 Result Update Pharmaceutical. Investment Period 12 months
1QFY2013 Result Update Pharmaceutical August 8, 2012 Aurobindo Pharma Performance Highlights Y/E march (` cr) 1QFY2013 4QFY2012 % chg (qoq) 1QFY2012 % chg (yoy) Net sales 1197 1171 2.3 1065 12.4 Other
More informationPhillips Carbon Black Ltd
4 Recommendation BUY Snail Pace Recovery CMP (06/02/2013) Rs. 85 Target Price Rs. 110 Sector Stock Details Carbon Black BSE Code 506590 NSE Code Bloomberg Code PHILIPCARB PHCB IN Market Cap (Rs crs) 293
More informationCCL Products BUY. Performance Update. CMP Target Price `278 `360. 3QFY2018 Result Update Coffee. Historical share price chart.
Feb-15 May-15 Aug-15 Oct-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 3QFY2018 Result Update Coffee February 5, 2018 CCL Products Performance Update Y/E March (` cr) Q3FY18 Q3FY17
More informationInox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart
4QFY216 Result Update Capital Goods May 11, 216 Inox Wind Performance Highlights Quarterly Data (Consolidated) ( ` cr) 4QFY16 4QFY15 % chg (yoy) 3QFY16 % chg (qoq) Total Income 1,829 93 96.6 941 94.2 EBITDA
More informationGarware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months
2QFY217 Result Update Textile November 16, 216 Garware Wall Ropes Performance Highlights Quarterly Data (`cr) 2QFY17 2QFY16 % yoy 1QFY17 % qoq Revenue 232 214 8.5 225 3.3 EBITDA 4 26 5.9 31 29.4 Margin
More informationITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months
3QFY2017 Result Update FMCG January 30, 2017 ITC Performance Highlights Quarterly result (Standalone) (` cr) 3QFY17 3QFY16 % yoy 2QFY17 %qoq Revenue 9,248 8,867 4.3 9,661 (4.3) EBITDA 3,546 3,475 2.1 3,630
More informationGoodyear India BUY. Company Update. CMP Target Price `515 `631. Company Update Tyres. 3-year Daily Price Chart. Key Financials
Company Update Tyres June 10, 2016 Goodyear India Company Update Expectation of normal monsoon to energize stagnant tractor demand: Goodyear India (GIL) is a leader in the farm tyre segment in India with
More informationMahindra & Mahindra Ltd.
Nov-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 2QFY2019 Result Update Automobile November 15, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr)
More informationHindustan Media Ventures
2QFY216 Result Update Media October 27, 215 Hindustan Media Ventures Performance Highlights Quarterly Data (` cr) 2QFY16 2QFY15 % yoy 1QFY15 % qoq Revenue 227 2 13.7 224 1.4 EBITDA 52 39 33.1 55 (4.5)
More informationHindustan Unilever Ltd.
. RESULT UPDATE 18 th July 2017 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 125 105 India Equity Institutional Research II Result Update - FY18 II 18th July, 2017 CMP INR 1158 Target INR 1206 MARKET
More informationCadila Healthcare NEUTRAL. Performance Highlights CMP. `495 Target Price - 4QFY2017 Result Update Pharmaceutical.
Feb-14 May-14 Aug-14 Nov-14 Feb-15 May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 4QFY2017 Result Update Pharmaceutical June 5, 2017 Cadila Healthcare Performance Highlights Y/E March (`
More informationApollo Hospitals Enterprise Ltd.
Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17. Volume No.. I Issue No. 154 Apollo Hospitals Enterprise Ltd. December 19, 2017 BSE Code: 508869 NSE Code: APOLLOHOSP
More informationFineotex Chemical Ltd
Company Update Decent Performance under Macroeconomic Pressure; Business Traction to Continue: Fineotex Chemical recorded decent set of result as consolidated sales grew by 1.1% YoY (largely in line) to
More informationHero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,718 Target Price `4,130. 1QFY2018 Result Update Automobile. 3-year price chart
1QFY2018 Result Update Automobile July 27, 2017 Hero MotoCorp Performance Highlights ACCUMULATE CMP `3,718 Target Price `4,130 Y/E March (` cr) 1QFY18 1QFY17 % chg (yoy) 4QFY17 % chg (qoq) Investment Period
More information